Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice.

Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert M.

Int J Pharm. 2005 Apr 11;293(1-2):281-90.

PMID:
15778066
2.

Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.

Routledge PA, Stargel WW, Barchowsky A, Wagner GS, Shand DG.

Br J Clin Pharmacol. 1989 Nov;28(5):593-7.

3.

Effect of cetamolol on epinephrine-induced hypokalemia.

Klausner MA, Irwin C, Mullane JF, Shand DG, Leese PT, Arnold JD, Wollberg W, Wagner NB, Wagner GS.

J Clin Pharmacol. 1988 Aug;28(8):751-6.

PMID:
2905711
4.

In support of cardiac chronotropic beta 2 adrenoceptors.

Brown JE, McLeod AA, Shand DG.

Am J Cardiol. 1986 Apr 25;57(12):11F-16F.

PMID:
3010692
5.

The effect of etodolac administration on renal function in patients with arthritis.

Shand DG, Epstein C, Kinberg-Calhoun J, Mullane JF, Sanda M.

J Clin Pharmacol. 1986 Apr;26(4):269-74.

PMID:
2939116
6.

A free lignocaine index as a guide to unbound drug concentration.

Routledge PA, Lazar JD, Barchowsky A, Stargel WW, Wagner GS, Shand DG.

Br J Clin Pharmacol. 1985 Dec;20(6):695-8.

7.

Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health.

Blain PG, Mucklow JC, Rawlins MD, Roberts DF, Routledge PA, Shand DG.

Br J Clin Pharmacol. 1985 Nov;20(5):500-2.

8.

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

Davis D, Grossman SH, Kitchell BB, Shand DG, Routledge PA.

Br J Clin Pharmacol. 1985 Feb;19(2):261-5.

9.
10.

Influence of cimetidine on verapamil kinetics and dynamics.

Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL.

Clin Pharmacol Ther. 1984 Oct;36(4):551-4.

PMID:
6478741
11.

Hemodynamic and metabolic responses to exercise after adrenoceptor blockade in humans.

McLeod AA, Brown JE, Kitchell BB, Sedor FA, Kuhn C, Shand DG, Williams RS.

J Appl Physiol Respir Environ Exerc Physiol. 1984 Mar;56(3):716-22.

PMID:
6142878
12.

Hemodynamic and metabolic responses to exercise after alpha 1-, beta 1-, and nonselective beta-adrenoceptor blockade in man.

McLeod AA, Brown JE, Kitchell BB, Sedor FA, Kuhn DC, Williams RS, Shand DG.

Am J Med. 1984 Feb 27;76(2A):97-100.

PMID:
6702866
14.

alpha 1-Acid glycoprotein and plasma lidocaine binding.

Shand DG.

Clin Pharmacokinet. 1984 Jan;9 Suppl 1:27-31.

PMID:
6705424
15.

Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia.

Pritchett EL, Hammill SC, Reiter MJ, Lee KL, McCarthy EA, Zimmerman JM, Shand DG.

Am J Cardiol. 1983 Nov 1;52(8):1007-12.

PMID:
6356859
16.

Effect of verapamil on left ventricular function at rest and during exercise in normal men.

D'Agostino HJ Jr, Pritchett EL, Shand DG, Jones RH.

J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):812-7.

PMID:
6195469
17.

Efficacy, safety, and pharmacokinetics of a concentration-maintaining regimen of intravenous pirmenol.

Reiter MJ, Hammill SC, Shand DG, Verghese C, McCarthy E, Pritchett EL.

Am J Cardiol. 1983 Jul;52(1):83-7.

PMID:
6858934
18.

Comparison of high-dose and medium-dose propranolol in the relief of exercise-induced myocardial ischemia.

Morris KG, Higginbotham MB, Coleman RE, Shand DG, Cobb FR.

Am J Cardiol. 1983 Jul;52(1):7-13.

PMID:
6858930
19.

How should the proper dose of a beta blocker be determined?

Shand DG.

Circulation. 1983 Jun;67(6 Pt 2):I86-8. No abstract available.

PMID:
6133650
20.
21.

Pharmacokinetic and pharmacodynamic effects of diltiazem.

Smith MS, Verghese CP, Shand DG, Pritchett EL.

Am J Cardiol. 1983 May 1;51(8):1369-74.

PMID:
6846164
22.

Differentiation of hemodynamic, humoral and metabolic responses to beta 1- and beta 2-adrenergic stimulation in man using atenolol and propranolol.

McLeod AA, Brown JE, Kuhn C, Kitchell BB, Sedor FA, Williams RS, Shand DG.

Circulation. 1983 May;67(5):1076-84.

PMID:
6299612
23.

Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacy.

McGowan FX, Reiter MJ, Pritchett EL, Shand DG.

Clin Pharmacol Ther. 1983 Apr;33(4):485-90.

PMID:
6831827
24.

Evidence for cardiac beta 2-adrenoceptors in man.

Brown JE, McLeod AA, Shand DG.

Clin Pharmacol Ther. 1983 Apr;33(4):424-8.

PMID:
6299641
25.

Propranolol decreases serum thyroxine as well as triiodothyronine in rats: a protein-binding effect.

Jurney TH, Smallridge RC, Routledge PA, Shand DG, Wartofsky L.

Endocrinology. 1983 Feb;112(2):727-32. No abstract available.

PMID:
6848369
26.

Is it safe to use intravenous verapamil to treat a patient who is taking oral verapamil?

Pritchett EL, Reiter MJ, Hammill SC, Stack R, Waugh RA, Shand DG.

Am Heart J. 1983 Feb;105(2):329-31. No abstract available.

PMID:
6823818
27.

High-performance liquid chromatographic analysis of diltiazem and its metabolite in plasma.

Verghese C, Smith MS, Aanonsen L, Pritchett EL, Shand DG.

J Chromatogr. 1983 Jan 14;272(1):149-55.

PMID:
6841534
28.

Lidocaine and its metabolites in canine plasma and myocardium.

Handel F, Luzzi FA, Wenger TL, Barchowsky A, Shand DG, Strauss HC.

J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):44-50. No abstract available.

PMID:
6186858
29.

Comparison of intravenous and oral verapamil dosing.

Reiter MJ, Shand DG, Pritchett EL.

Clin Pharmacol Ther. 1982 Dec;32(6):711-20.

PMID:
7140136
30.

Pirmenol kinetics and effective oral dose.

Hammill SC, Shand DG, Harrell FE Jr, Zimmerman JM, Reiter MJ, Verghese C, Pritchett EL.

Clin Pharmacol Ther. 1982 Dec;32(6):686-91.

PMID:
7140134
31.

Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen.

Reiter MJ, Shand DG, Aanonsen LM, Wagoner R, McCarthy E, Pritchett EL.

Am J Cardiol. 1982 Oct;50(4):716-21.

PMID:
7124631
32.

Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats.

Kaelin WG Jr, Shrivastav S, Shand DG, Jirtle RL.

Cancer Res. 1982 Oct;42(10):3944-9.

33.

Hemodynamic effects of the antiarrhythmic drug pirmenol.

Phillips HR, Stack RS, Davis DD, Morris KG, Lee KL, Shand DG, Pritchett EL.

Clin Pharmacol Ther. 1982 Aug;32(2):235-9.

PMID:
7094511
34.

Plasma norepinephrine in the evaluation of baroreceptor function in humans.

Grossman SH, Davis D, Gunnells JC, Shand DG.

Hypertension. 1982 Jul-Aug;4(4):566-71.

35.

Beta-adrenergic blocking drugs after acute myocardial infarction.

Shand DG.

Mod Concepts Cardiovasc Dis. 1982 Jul;51(7):103-6. No abstract available.

PMID:
6126802
36.

On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.

Barchowsky A, Shand DG, Stargel WW, Wagner GS, Routledge PA.

Br J Clin Pharmacol. 1982 Mar;13(3):411-5.

37.

Therapeutic drug monitoring of antiarrhythmic agents.

Brown JE, Shand DG.

Clin Pharmacokinet. 1982 Mar-Apr;7(2):125-48. Review. No abstract available.

PMID:
7039925
38.

Diazepam and lidocaine plasma protein binding in renal disease.

Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA.

Clin Pharmacol Ther. 1982 Mar;31(3):350-7.

PMID:
7037263
39.

Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics.

Hammill SC, Shand DG, Routledge PA, Hindman MC, Baker JT, Pritchett EL.

Circulation. 1982 Feb;65(2):369-75.

PMID:
7053896
40.

Atenolol: a long-acting beta 1- adrenoceptor antagonist.

McLeod AA, Shand DG.

Ann Intern Med. 1982 Feb;96(2):244-5. No abstract available.

PMID:
6120670
41.

Saliva concentrations of lidocaine and its metabolites in man.

Barchowsky A, Stargel WW, Shand DG, Routledge PA.

Ther Drug Monit. 1982;4(4):335-9.

PMID:
7157457
42.

Control of lidocaine therapy: new perspectives.

Routledge PA, Stargel WW, Barchowsky A, Wagner GS, Shand DG.

Ther Drug Monit. 1982;4(3):265-70.

PMID:
7135456
43.

Biological determinants of altered pharmacokinetics in the elderly.

Shand DG.

Gerontology. 1982;28 Suppl 1:8-17. Review.

PMID:
7044905
44.

Pharmacokinetic studies: their role in determining therapeutic efficacy of agents designed to prevent sudden death.

Shand DG, Pritchett EL, Hammill SC, Stargel WW, Wagner GS.

Ann N Y Acad Sci. 1982;382:238-46. Review. No abstract available.

PMID:
7044243
45.

Lignocaine disposition in blood in epilepsy.

Routledge PA, Stargel WW, Finn AL, Barchowsky A, Shand DG.

Br J Clin Pharmacol. 1981 Nov;12(5):663-6.

46.

Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading.

Stargel WW, Shand DG, Routledge PA, Barchowsky A, Wagner GS.

Am Heart J. 1981 Nov;102(5):872-6.

PMID:
7304395
47.

Reduced verapamil clearance during long-term oral administration.

Shand DG, Hammill SC, Aanonsen L, Pritchett EL.

Clin Pharmacol Ther. 1981 Nov;30(5):701-6.

PMID:
7297027
48.

The artifactual nature of heparin-induced drug protein-binding alterations.

Brown JE, Kitchell BB, Bjornsson TD, Shand DG.

Clin Pharmacol Ther. 1981 Nov;30(5):636-43.

PMID:
6794969
49.

Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.

Routledge PA, Shand DG, Barchowsky A, Wagner G, Stargel WW.

Clin Pharmacol Ther. 1981 Aug;30(2):154-7.

PMID:
7249498
50.

The method of separate exponentials: a simple aid to devising intravenous drug-loading regimens.

Shand DG, Desjardins RE, Bjornsson TD, Hammill SC, Pritchett EL.

Clin Pharmacol Ther. 1981 Apr;29(4):542-7.

PMID:
7471622

Supplemental Content

Loading ...
Support Center